The use of immunoglobulin therapy for patients with primary immune deficiency: an evidence-based practice guideline
- PMID: 19962579
- DOI: 10.1016/j.tmrv.2009.09.011
The use of immunoglobulin therapy for patients with primary immune deficiency: an evidence-based practice guideline
Abstract
The standard treatment for patients with primary antibody deficiency is immunoglobulin (IG), but the care of these patients is complex. These guidelines, initiated by the Canadian Blood Services and the National Advisory Committee on Blood and Blood Products, have been developed to facilitate and standardize the care of these patients by the various physician specialties that are responsible for their care. A panel of national expert immunologists and methodologists developed salient clinical questions; and a systematic, expert, and bibliography literature search up to July 2008 was conducted. One thousand eighty-seven citations were retrieved, and 102 reports were used in the preparation of this guideline. The recommendations provide guidance (1) on the complexity of the treatment of these patients; (2) the established benefits of IG on morbidity and mortality; (3) dosage, routes of administration, and management of reactions; (4) the various IG formulations available; (5) vaccination of these patients; and (6) research priorities.
Similar articles
-
The use of immunoglobulin therapy for patients undergoing solid organ transplantation: an evidence-based practice guideline.Transfus Med Rev. 2010 Jan;24 Suppl 1:S7-S27. doi: 10.1016/j.tmrv.2009.09.010. Transfus Med Rev. 2010. PMID: 19962580 Review.
-
Guidelines on the use of intravenous immune globulin for hematologic conditions.Transfus Med Rev. 2007 Apr;21(2 Suppl 1):S9-56. doi: 10.1016/j.tmrv.2007.01.001. Transfus Med Rev. 2007. PMID: 17397769
-
Guidelines on the use of intravenous immune globulin for neurologic conditions.Transfus Med Rev. 2007 Apr;21(2 Suppl 1):S57-107. doi: 10.1016/j.tmrv.2007.01.002. Transfus Med Rev. 2007. PMID: 17397768
-
Evidence-based guidelines on the use of intravenous immune globulin for hematologic and neurologic conditions.Transfus Med Rev. 2007 Apr;21(2 Suppl 1):S3-8. doi: 10.1016/j.tmrv.2007.01.004. Transfus Med Rev. 2007. PMID: 17397767
-
The patient: Emerging clinical applications of intravenous immunoglobulin.Pharmacotherapy. 2005 Nov;25(11 Pt 2):85S-93S. doi: 10.1592/phco.2005.25.11part2.85S. Pharmacotherapy. 2005. PMID: 16229679 Review.
Cited by
-
Primary immunodeficiency.Allergy Asthma Clin Immunol. 2011 Nov 10;7 Suppl 1(Suppl 1):S11. doi: 10.1186/1710-1492-7-S1-S11. Allergy Asthma Clin Immunol. 2011. PMID: 22165913 Free PMC article.
-
Passive transfer of anti-HBc after intravenous immunoglobulin administration in patients with cancer: a retrospective chart review.Lancet Haematol. 2018 Oct;5(10):e474-e478. doi: 10.1016/S2352-3026(18)30152-2. Lancet Haematol. 2018. PMID: 30290904 Free PMC article.
-
The Evolutionary Scenario of Pediatric Unclassified Primary Antibody Deficiency to Adulthood.J Clin Med. 2023 Jun 22;12(13):4206. doi: 10.3390/jcm12134206. J Clin Med. 2023. PMID: 37445241 Free PMC article.
-
Screening for Antibody Deficiencies in Adults by Serum Electrophoresis and Calculated Globin.J Clin Immunol. 2023 Nov;43(8):1873-1880. doi: 10.1007/s10875-023-01536-1. Epub 2023 Jul 28. J Clin Immunol. 2023. PMID: 37505322
-
Patient-reported outcomes in patients with primary immunodeficiency diseases in Japan: baseline results from a prospective observational study.Front Immunol. 2023 Sep 27;14:1244250. doi: 10.3389/fimmu.2023.1244250. eCollection 2023. Front Immunol. 2023. PMID: 37828988 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources